11.11.2021 • News

Sale of Solenis to Platinum Equity Closes

With the receipt of all approvals, BASF and Clayton, Dubilier & Rice (CD&R) have closed the sale of water treatment company Solenis to Platinum Equity. The transfer to the new private equity investor for an enterprise value of $5.25 billion includes net debt of around $2.5 billion.

The buyer and sellers announced the deal this past July. At the time of sale, BASF held 49% of the two-year-old company, the investment group 51%, together with Solenis’ management.

The ownership structure emerged from CD&R’s $1.8 billion purchase of the water chemicals unit of US chemical producer Ashland in 2018. In 2019, the German group folded its water chemicals business into the new business.

BASF said the divestment of its shares in Solenis will be reflected in its financial reporting for the current fourth quarter as net income from shareholdings.

With more than 5,200 employees, Solenis produces mainly specialty chemicals used in water treatment and paper manufacturing. It also makes products for other water-intensive industries including chemical processing, mining and oil production. The Wilmington, Delaware-based US company reported sales of $ 3billion for fiscal year 2021 (Sept. 30).

Author: Dede Williams, Freelance Journalist

With receipt of all approvals, BASF and Clayton, Dubilier & Rice have closed...
With receipt of all approvals, BASF and Clayton, Dubilier & Rice have closed the sale of water treatment company Solenis to Platinum Equity. The transfer to the new private equity investor for an enterprise value of $5.25 million includes net debt of around $2.5 billion. (c) Solenis

Interview

Driving Sustainability Through Collaboration
Building Green Practices Across the Chemical Supply Chain

Driving Sustainability Through Collaboration

Together for Sustainability (TfS) is a pioneering, member-led initiative working to accelerate sustainable and resilient chemical supply chains. TfS President Jennifer Jewson discusses the origins of TfS, its evolving goals, its present-day challenges, and the initiative’s enduring impact and outlook for the future.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read